DexCom Past Earnings Performance
Past criteria checks 5/6
DexCom has been growing earnings at an average annual rate of 28.5%, while the Medical Equipment industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 21.3% per year. DexCom's return on equity is 27.4%, and it has net margins of 16.9%.
Key information
28.5%
Earnings growth rate
28.0%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 21.3% |
Return on equity | 27.4% |
Net Margin | 16.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Apr 25Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price
Apr 12DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Mar 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Mar 04DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital
Jan 15DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing
Jan 01DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Dec 18A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Dec 05At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Nov 21DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
Sep 28DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13DexCom (NASDAQ:DXCM) Seems To Use Debt Quite Sensibly
Nov 25Returns Are Gaining Momentum At DexCom (NASDAQ:DXCM)
Oct 21Dexcom launches G7 glucose monitoring system in parts of Europe, Asia
Oct 04What Is DexCom, Inc.'s (NASDAQ:DXCM) Share Price Doing?
Sep 24Revenue & Expenses Breakdown
How DexCom makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,935 | 667 | 1,242 | 545 |
31 Mar 24 | 3,802 | 639 | 1,208 | 528 |
31 Dec 23 | 3,622 | 542 | 1,185 | 506 |
30 Sep 23 | 3,403 | 377 | 1,174 | 486 |
30 Jun 23 | 3,198 | 358 | 1,135 | 465 |
31 Mar 23 | 3,023 | 293 | 1,085 | 467 |
31 Dec 22 | 2,910 | 341 | 1,008 | 484 |
30 Sep 22 | 2,793 | 244 | 936 | 605 |
30 Jun 22 | 2,673 | 230 | 900 | 623 |
31 Mar 22 | 2,572 | 258 | 837 | 631 |
31 Dec 21 | 2,449 | 217 | 811 | 604 |
30 Sep 21 | 2,319 | 577 | 749 | 487 |
30 Jun 21 | 2,170 | 562 | 709 | 445 |
31 Mar 21 | 2,027 | 530 | 660 | 396 |
31 Dec 20 | 1,927 | 550 | 618 | 360 |
30 Sep 20 | 1,821 | 231 | 574 | 320 |
30 Jun 20 | 1,716 | 205 | 539 | 299 |
31 Mar 20 | 1,601 | 148 | 541 | 288 |
31 Dec 19 | 1,476 | 101 | 516 | 274 |
30 Sep 19 | 1,351 | -171 | 499 | 252 |
30 Jun 19 | 1,222 | -170 | 479 | 236 |
31 Mar 19 | 1,128 | -130 | 452 | 214 |
31 Dec 18 | 1,032 | -127 | 433 | 417 |
30 Sep 18 | 915 | 43 | 414 | 191 |
30 Jun 18 | 833 | -5 | 393 | 184 |
31 Mar 18 | 761 | -33 | 368 | 182 |
31 Dec 17 | 719 | -50 | 349 | 185 |
30 Sep 17 | 669 | -48 | 336 | 180 |
30 Jun 17 | 633 | -65 | 327 | 181 |
31 Mar 17 | 599 | -88 | 311 | 172 |
31 Dec 16 | 573 | -66 | 286 | 156 |
30 Sep 16 | 533 | -57 | 268 | 141 |
30 Jun 16 | 490 | -80 | 245 | 125 |
31 Mar 16 | 445 | -64 | 221 | 113 |
31 Dec 15 | 402 | -58 | 198 | 101 |
30 Sep 15 | 356 | -58 | 173 | 94 |
30 Jun 15 | 319 | -20 | 155 | 85 |
31 Mar 15 | 285 | -23 | 140 | 76 |
31 Dec 14 | 259 | -22 | 128 | 69 |
30 Sep 14 | 227 | -26 | 116 | 60 |
30 Jun 14 | 201 | -27 | 104 | 52 |
31 Mar 14 | 178 | -31 | 94 | 47 |
31 Dec 13 | 160 | -30 | 84 | 42 |
30 Sep 13 | 142 | -36 | 78 | 39 |
Quality Earnings: DXCM has high quality earnings.
Growing Profit Margin: DXCM's current net profit margins (16.9%) are higher than last year (11.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DXCM has become profitable over the past 5 years, growing earnings by 28.5% per year.
Accelerating Growth: DXCM's earnings growth over the past year (86.5%) exceeds its 5-year average (28.5% per year).
Earnings vs Industry: DXCM earnings growth over the past year (86.5%) exceeded the Medical Equipment industry 5.5%.
Return on Equity
High ROE: Whilst DXCM's Return on Equity (27.4%) is high, this metric is skewed due to their high level of debt.